Milestone Pharmaceuticals nets $17 mln in Series B funding round
Milestone Pharmaceuticals Inc, a Canadian drug developer focused on cardiovascular diseases, has raised US$17 million in Series B funding. U.S. venture capital firm Domain Associates led the round with participation from the company's existing investors, including the Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the deal, Domain's Debra Liebert was added to Milestone's board of directors. Update: The company, which has its headquarters in Montréal, said proceeds of the round will be used to complete Phase 2 clinical development of its lead product. Founded in 2005, Milestone has raised more than US$30 million in venture funding to date.
15 June 2015•5 mins read
